Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MINNETONKA ENTERING Rx MARKET WITH TRANSDERMAL WART REMOVAL

Executive Summary

MINNETONKA ENTERING Rx MARKET WITH TRANSDERMAL WART REMOVAL product, the firm's corporate VP Robert Hebeisen told the New York Society of Security Analysts on Dec. 4. Trademarked Tran-sal, the product consists of salicylic acid in a transdermal patch. Minnetonka plans to launch its first prescription product in March. The firm maintains that regulatory approval from FDA is not needed to market the product. Hebeisen said that in clinical tests Tran-sal was shown to be "highly effective" in treating warts and less irritating than the leading prescription wart removers. Minnetonka said it developed the product in collaboration with the dermatology department of a mid-western university. Tran-sal will be sold in kits containing 40 transdermal pads and adhesive tape at a suggested retail price of $18.50 per kit. Minnetonka's Davron professional skin care group will market the product. The division curently markets a variety of professional soaps and skin care items through 45 independent manufacturer representatives and several hospital supply distributors. Minnetonka said the division accounts for less than 5% of corporate sales. Minnetonka had 1985 sales of approximately $124 mil.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS011157

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel